Quarterly report [Sections 13 or 15(d)]

Revenues from Contracts and Significant Customers (Tables)

v3.26.1
Revenues from Contracts and Significant Customers (Tables)
3 Months Ended
Mar. 31, 2026
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

Three Months Ended March 31, 

($ in thousands)

  ​ ​ ​

2026

  ​ ​ ​

2025

Emrosi

$

6,252

$

2,070

Qbrexza

5,028

5,161

Accutane

3,314

3,655

Foam franchise products (Amzeeq & Zilxi)

1,050

1,526

Other / legacy product revenue

277

727

Other revenue

117

 

Total net revenue

$

16,038

$

13,139